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(adherent), $12,619 (partially adherent) and $8,675 (non-adher-
ent). The adherent class had a lower average cost than the non-
adherent class in all the cost categories but drug costs were
$1,939 higher (all p-values <0.05). CONCLUSION: Multiple
indicators of adherence to antipsychotic medication capture het-
erogeneity in non-adherence behaviors, which can be modeled
using latent classes, so deﬁne non-adherence casemix.
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STARTING DOSE AND PERSISTENCE FOR ZIPRASIDONE
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OBJECTIVE: To determine the relationship between ziprasidone
starting dose and persistence among patients diagnosed with
schizophrenia. METHODS: Adult Medicaid recipients diag-
nosed with schizophrenia and having ziprasidone prescription
claims between July 1, 2001 and September 30, 2003 were cat-
egorized by starting dosage: low (20–60mg) n = 517; medium
(61mg–119mg) n = 339; and high (120–160mg) n = 341. Per-
sistence was measured using reﬁll patterns, allowing 15-day gaps
between expected reﬁll dates, and compared across starting doses
using Chi-Square tests. Multivariate logistic analysis explored
the simultaneous impact of age, gender, race, and year of treat-
ment initiation in addition to starting dose. RESULTS: Discon-
tinuation rates across the study period (maximum 30 months)
were greater for patients initiated with low (p = 0.001) and
medium dose (p = 0.02) than for high dose patients. Discontin-
uation rates were not statistically different for low and medium
doses. Discontinuation rates at 365, 180, and 90 days were
higher for low dose than high dose (p < 0.05) but not signiﬁ-
cantly different between low and medium or medium and high
doses. These results were similar in the multivariate models.
CONCLUSIONS: Schizophrenia patients started on high doses
of ziprasidone have greater persistence up to 21/2 years than those
who start on low doses.
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OBJECTIVES: The primary objective compared antipsychotic
non-adherence rates of outpatients with schizophrenia or
schizoaffective disorder as assessed by electronic monitoring vs.
prescriber ratings. Secondary objectives evaluated the relation-
ship between electronically-determined antipsychotic adherence
with (1) various baseline patient characteristics and (2) prospec-
tively assessed symptom severity, quality of life (QoL) and cog-
nition. METHODS: Adult outpatients with schizophrenia or
schizoaffective DSM-IV diagnosis, taking a single oral antipsy-
chotic, and who signed informed consent were eligible. Adher-
ence was measured via electronic-monitored medication vial
caps, prescriber report, patient self-report and research assistant
report, at baseline and monthly for up to six-months, as were
symptom severity (PANSS) and QoL (SQLS, LOF, PSP). Patients
were non-adherent if adherence was <70% for two or more
months during the six-month study. A single cognition assess-
ment (BACS) was performed. RESULTS: Sixty-one patients
(mean age 44.3, b9.1 years, 51% female, illness duration 21.2,
b 10.7 years) were included. Antipsychotic non-adherence detec-
tion was signiﬁcantly higher with electronic monitoring (57%)
vs. prescriber assessment (7%; p < 0.0001, N = 60) and vs.
patient self-assessment (5%; p < 0.0001), but was not different
from research assistant assessment (54%; p < 0.67). While the
total number of patients classiﬁed as adherent and non-adherent
by research assistants and electronic monitoring were similar,
disagreement in assignment occurred in 36% of cases. Poorer
mean adherence was associated with baseline characteristics of
less than high school education (p < 0.0001), non-Caucasian race
(p = 0.001), and more severe symptoms (p = 0.001). Lower mean
adherence rates were also associated with worse mean six-month
symptom (PANSS total; p < 0.002) and lower functioning on one
of three QoL scales (SQLS; p < 0.03) ratings. No relationship
was found between adherence and cognition. CONCLUSION:
In patients with schizophrenia and schizoaffective disorder, non-
adherence is signiﬁcantly underestimated/underreported by pre-
scribers and patients. Results suggest non-adherence with
antipsychotic medication therapy is associated with worse symp-
toms, poorer QoL, less than high school education and non-
Caucasian race.
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OBJECTIVES: To evaluate long-term clinical and economic out-
comes in patients participating in the ongoing Electronic Schiz-
ophrenia Treatment Adherence Registry in Germany, who were
initiated on long-acting injectable risperidone (LAIR). Baseline
and retrospective data will be presented. METHODS: Data are
collected via a secured web-based system for 12 months retro-
spectively and for 2 years prospectively. Data collected include
patient demographics, treatment and hospitalisation history,
reason for initiating new antipsychotic treatment, Clinical
Global Impression—Severity (CGI-S), Global Assessment of
Functioning (GAF) and adverse events. RESULTS: Complete
baseline and retrospective data are available for 744 patients.
Mean (±SD) age is 41.0 years (±12.2), 56% of patients are male,
and 97% have a diagnosis of schizophrenia or schizoaffective
disorder. The mean (±SD) duration of illness at the time of LAIR
initiation is 9.2 (±9.1) years. Eighty-six percent of patients had
a CGI-S score of moderate (30.5%), marked (35.5%) or severe
(20.3%). The mean (±SD) GAF score was 46 (±15). Seventy-two
percent of patients had at least one hospitalisation during the
year before LAIR initiation; 39% patients received oral atypi-
cals, 5% oral conventionals, 15% depot conventionals, and 31%
received different types of antipsychotics simultaneously or
sequentially in the year preceding LAIR initiation. For 10% of
patients, no retrospective medication information was indicated.
The most frequent reasons for LAIR initiation were lack of com-
pliance (37%), insufﬁcient response (27%), and unacceptable
tolerability (16%) with the previous medication(s). Fifty-three
percent of patients started on 25mg/14 days of long-acting
risperidone, 31% on 37.5mg/14 days and 16% on 50mg/14
days. CONCLUSIONS: Patients in this sample demonstrate dis-
tinct symptomatology and impairment in functioning. Despite a
considerable proportion of patients previously treated with novel
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antipsychotics, lack of efﬁcacy or tolerability and poor compli-
ance remain frequent reasons for change of therapy.
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OBJECTIVES: E-STAR is an ongoing, international, observa-
tional survey evaluating long-term clinical and economic out-
comes in patients switched to a new antipsychotic. METHODS:
Data are collected via a secured web-based system, retrospec-
tively for 12-months and prospectively for two-years. Patient
demographics, treatment and hospitalisation history, reason for
initiating new treatment, Clinical Global Impression—Severity
(CGI-S), Global Assessment of Functioning (GAF) and adverse
event data are collected. RESULTS: Complete baseline and ret-
rospective data are currently available for 1920 patients enrolled:
Germany (n = 744), Spain (n = 709), Australia (n = 467). Patients
reported here switched to long acting injectable (LAI) risperidone
Mean age was 39.5 years (SD 11.8; range 37.5–41); majority
were male (mean 61%; range 56–70%). 98% had a diagnosis of
schizophrenia or schizoaffective disorder (range 98–100%).
Mean duration of illness was 10.8 years (SD 9.3; range 9.2–12.6
years). Majority of patients (>80%) at baseline had a CGI-S
score of 4–6 indicating that patients were moderately (35%),
markedly (34%) or severely (18%) ill. The GAF scores were
similar across countries (mean 46; SD 15; range 43–48). There
were country differences in hospitalisation history during the 12-
month retrospective period: 28%, 70%, and 17% of patients in
Germany, Spain and Australia respectively had no hospitalisa-
tions; for patients with hospitalisations, the mean number of
days hospitalised per patient was 58.2 (SD 53.1), 38.3 (SD 51.1),
and 66.9 (SD 90.3) respectively. Prior to the switch to (LAI)
risperidone, 67–90% patients were taking oral atypicals,
27–35% oral conventionals, and 22–52% depot conventionals.
The most frequent reason for switching was compliance:
Germany (37%), Australia (52%), Spain (30%). CONCLU-
SIONS: Compliance remains an important treatment issue even
for those treated with atypicals. Continued enrollment, and
follow-up will enable a better understanding of a broader range
of treatment patterns in schizophrenic patients
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OBJECTIVES: E-STAR is an international, non-interventional,
observational study of clinical and economic outcomes in schiz-
ophrenia/schizoaffective patients who switch to a new antipsy-
chotic. METHODS: Data over a 12-month retrospective and 24
month prospective period from in- or out-patients who start on
a new antipsychotic medication are collected via a secure,
privacy-protected web-site. All data are automatically checked
against validation rules at the point of entering the study. The
validation rules are established in consultation with specialists 
in data analysis and key opinion leaders, and are designed to
prevent missing data, duplicate data and data outside pre-
established, reasonable ranges. These require conﬁrmation by the
physician before the system will accept them. If data is entered
incorrectly, the physician submits correction requests via an
audited online data change request system. A further supple-
mental audit process is used to control quality of uploaded data.
This process uses monthly reports to identify potential inconsis-
tencies within the dataset after data has been validated at entry.
RESULTS: Uploaded data undergoing quality control checks,
requiring adjustment by physicians, is minimal. Audit reports
have helped redress data entry training issues, further enhancing
data accuracy. Analysis is only conducted on patients after res-
olution of outstanding supplemental data queries. Conclusion:
This largely automated three stage quality control process is
important to the implementation of non-interventional, obser-
vational research such as this, where the goal is to study out-
comes in a generalisable, representative patient cohort. This
permits the inclusion of patients from a broad geographic region,
which will add signiﬁcantly to our understanding of the use of
anti-psychotics in actual clinical practice, outside of the inﬂuence
of clinical trial settings. This also allows for much faster analy-
sis and presentation of robust, pragmatic outcomes data.
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OBJECTIVES: Compare patient- and caregiver-reported out-
comes on 25 objective questions contained within the 51-item
Schizophrenia Outcomes Assessment Project (SOAP) quality of
life survey. METHODS: In total, 1500 community-residing indi-
viduals with schizophrenia in ﬁve states (Massachusetts, South
Carolina, Wisconsin, Arizona, Washington) completed SOAP-51
survey at baseline and weeks four, ﬁve, and 12. Previously, factor
analysis indicated that SOAP-51 had eight factors (satisfaction,
self concept, work/role, mental health, interpersonal, medication
effects, activities of daily living, and physical function) with
Cronbach alphas ranging from 0.728–0.937 and test/retest intr-
aclass correlations >0.70 for all but one factor. An expert panel
identiﬁed 25 SOAP items that could be objectively measured.
This 25-item subset was given to each patient’s primary caregiver
concurrent with each patient’s SOAP-51 administration. Care-
givers were asked to answer each item in two ways: 1) What is
your objective response?; and 2) What do you think is the
patient’s response? Three correlation sets were performed for
week-four responses: a) caregiver’s objective responses compared
to caregiver’s estimation of patient’s responses (Correlation A);
b) caregiver’s objective response compared to patient’s responses
(Correlation B); and c) caregiver’s estimation of patient’s
responses compared to patient’s responses (Correlation C).
RESULTS: Strongest correlations occurred in Correlation A
[factor scores for caregiver’s objective responses compared to
caregiver’s estimation of patient’s responses (0.534–0.862)];
lowest for Correlation B [caregiver’s objective response com-
pared to patient’s responses (-0.292–0.367)]; and intermediate
for Correlation C [caregiver’s estimation of patient’s responses
compared to patient’s responses (-0.353–0.564)]. Physical func-
tion factor correlations were the strongest in Correlation A
(0.862), but the lowest in Correlation B (-0.292) and C (-0.353).
CONCLUSIONS: Caregiver objective assessments of indivi-
duals with schizophrenia can vary markedly from patient-
reported outcomes, but asking caregivers to view the world
through the eyes of the patient closes this gap. Asking caregivers
